相似文献
1
TLR activation and ionizing radiation induce strong immune responses against multiple tumor entities.
Oncoimmunology. 2015 May 7;4(11):e1042201. doi: 10.1080/2162402X.2015.1042201. eCollection 2015 Nov.
2
Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.
Oncotarget. 2015 Mar 10;6(7):4663-76. doi: 10.18632/oncotarget.3081.
3
Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses.
Oncoimmunology. 2016 Sep 9;5(11):e1232219. doi: 10.1080/2162402X.2016.1232219. eCollection 2016.
4
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
J Immunother Cancer. 2019 Sep 11;7(1):244. doi: 10.1186/s40425-019-0724-8.
5
CD4 T Cell and NK Cell Interplay Key to Regression of MHC Class I Tumors upon TLR7/8 Agonist Therapy.
Cancer Immunol Res. 2017 Aug;5(8):642-653. doi: 10.1158/2326-6066.CIR-16-0334. Epub 2017 Jun 21.
6
Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
J Immunol. 2009 May 1;182(9):5217-24. doi: 10.4049/jimmunol.0803826.
7
Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
J Immunotoxicol. 2009 Dec;6(4):257-65. doi: 10.3109/15476910903286733.
8
Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Hum Vaccin Immunother. 2015;11(4):851-69. doi: 10.1080/21645515.2015.1009814.
9
Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance.
Cancer Res. 2011 Aug 1;71(15):5123-33. doi: 10.1158/0008-5472.CAN-10-3903. Epub 2011 Jun 22.
10
Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer.
Oncogene. 2008 Jan 7;27(2):200-7. doi: 10.1038/sj.onc.1210909.
引用本文的文献
1
The innate defenders: a review of natural killer cell immunotherapies in cancer.
Front Immunol. 2024 Dec 23;15:1482807. doi: 10.3389/fimmu.2024.1482807. eCollection 2024.
2
The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy.
Pharmaceutics. 2022 Jun 10;14(6):1228. doi: 10.3390/pharmaceutics14061228.
3
The expression profile of RNA sensors in colorectal cancer and its correlation with cancer stages.
Transl Cancer Res. 2019 Aug;8(4):1351-1363. doi: 10.21037/tcr.2019.07.45.
4
Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases.
Int J Mol Sci. 2021 Dec 13;22(24):13397. doi: 10.3390/ijms222413397.
5
Inflammation and tumor progression: signaling pathways and targeted intervention.
Signal Transduct Target Ther. 2021 Jul 12;6(1):263. doi: 10.1038/s41392-021-00658-5.
6
Differential Effects of Trp53 Alterations in Murine Colorectal Cancer.
Cancers (Basel). 2021 Feb 15;13(4):808. doi: 10.3390/cancers13040808.
7
Review of the Efficacy and Mechanisms of Traditional Chinese Medicines as a Therapeutic Option for Ionizing Radiation Induced Damage.
Front Pharmacol. 2021 Feb 15;12:617559. doi: 10.3389/fphar.2021.617559. eCollection 2021.
8
Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming.
Front Cell Dev Biol. 2021 Jan 11;8:607209. doi: 10.3389/fcell.2020.607209. eCollection 2020.
9
The age-dependent effect of high-dose X-ray radiation on NFκB signaling, structure, and mechanical behavior of the intervertebral disc.
Connect Tissue Res. 2020 May-Jul;61(3-4):399-408. doi: 10.1080/03008207.2019.1703963. Epub 2019 Dec 26.
10
Targeting the Innate Immune Kinase IRAK1 in Radioresistant Cancer: Double-Edged Sword or One-Two Punch?
Front Oncol. 2019 Nov 13;9:1174. doi: 10.3389/fonc.2019.01174. eCollection 2019.
本文引用的文献
1
Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.
Oncotarget. 2015 Mar 10;6(7):4663-76. doi: 10.18632/oncotarget.3081.
2
A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.
Int J Cancer. 2014 Aug 15;135(4):820-9. doi: 10.1002/ijc.28711. Epub 2014 Jan 17.
3
Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.
Lancet Oncol. 2014 Jan;15(1):96-105. doi: 10.1016/S1470-2045(13)70530-8. Epub 2013 Dec 11.
4
Trial Watch: Anticancer radioimmunotherapy.
Oncoimmunology. 2013 Sep 1;2(9):e25595. doi: 10.4161/onci.25595. Epub 2013 Jul 3.
5
Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy.
Cancer Cell. 2013 Nov 11;24(5):589-602. doi: 10.1016/j.ccr.2013.09.014. Epub 2013 Oct 24.
6
Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.
Blood. 2013 Jan 10;121(2):251-9. doi: 10.1182/blood-2012-05-432393. Epub 2012 Oct 18.
7
Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy.
Oncoimmunology. 2012 Jul 1;1(4):407-408. doi: 10.4161/onci.20074.
8
Antiviral applications of Toll-like receptor agonists.
J Antimicrob Chemother. 2012 Apr;67(4):789-801. doi: 10.1093/jac/dkr588. Epub 2012 Jan 18.
9
Taking dendritic cells into medicine.
Nature. 2007 Sep 27;449(7161):419-26. doi: 10.1038/nature06175.
10
In situ photoimmunotherapy: a tumour-directed treatment for melanoma.
Br J Dermatol. 2006 Dec;155(6):1287-92. doi: 10.1111/j.1365-2133.2006.07514.x.
Zotero 插件